1 / 5

PSMA-based therapies have been proven effective for advanced prostate cancer

PSMA-based therapy is an effective treatment option that is offered to patients with metastasised prostate cancer with disease progression despite hormone therapy or chemotherapy.

6676
Télécharger la présentation

PSMA-based therapies have been proven effective for advanced prostate cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PSMA-based therapy is an effective treatment option that is offered to patients with metastasised prostate cancer with disease progression despite hormone therapy or chemotherapy.

  2. PSMA-based therapies have been proven effective for patients with advanced prostate cancer for whom surgical and other medical options have already exhausted themselves. They offer a new ray of hope. The Department of Nuclear Medicine at Fortis Memorial Research Institute (FMRI), Gurugram, India, has treated more than 30 new patients of Castration Resistance Prostate Cancer (CRPC) with Ac225 PSMA Therapy. The results are extremely promising with 75-80% of patients showing evidences of significant radiological and biochemical response with prolonged duration of response.

  3. Cecific membrane antigen-positive melinical trials have shown that targeted radiation therapy 225Ac-PSMA-617 has produced high response rate among men with with prostate-sptastatic, castration-resistant prostate cancer.

  4. At the 2018 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), a research was presented that demonstrated the benefit of providing earlier Lu-177 PSMA Radioligand Therapy to patients with metastatic prostate cancer, which until now was only used on patients with advanced stage of the disease. The research demonstrated a potential survival benefit and a superior response after early initiation of the therapy - patients who demonstrated a PSA decline of more than 50% after at least two PRLT cycles lived significantly longer.

  5. For more information do call Dr. Ishita Sen on +91 98111 27080, or write to us at info@nuclearmedicinetherapy.in. You can also visit our website to request for an opinion: www.nuclearmedicinetherapy.in

More Related